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Abstract
Thrombotic microangiopathy (TMA) is a pathological
process involving thrombocytopenia, microangiopathic hae-
molytic anaemia and microvascular occlusion. TMA is
common to haemolytic uraemic syndrome (HUS) associated
with shiga toxin or invasive pneumococcal infection, atypical
HUS (aHUS), thrombotic thrombocytopenic purpura (TTP)
and other disorders including malignant hypertension. HUS
complicating infection with shiga toxin-producing
Escherichia coli (STEC) is a signiﬁcant cause of acute renal
failure in children worldwide, occurring sporadically or in
epidemics. Studies in aHUS have revealed genetic and ac-
quired factors leading to dysregulation of the alternative
complement pathway. TTP has been linked to reduced
activity of the ADAMTS13 cleaving protease (typically with
an autoantibody to ADAMTS13) with consequent disruption
of von Willebrand factor multimer processing. However, the
convergence of pathogenic pathways and clinical overlap
create diagnostic uncertainty, especially at initial presentation.
Furthermore, recent developments are challenging estab-
lished management protocols. This review addresses the
current understanding of molecular mechanisms underlying
TMA, relating these to clinical presentation with an emphasis
on renal manifestations. A diagnostic and therapeutic ap-
proach is presented, based on international guidelines,
disease registries and published trials. Early treatment
remains largely empirical, consisting of plasma replacement/
exchange with the exception of childhood STEC-HUS or
pneumococcal sepsis. Emerging therapies such as the comp-
lement C5 inhibitor eculizumab for aHUS and rituximab for
TTP are discussed, as is renal transplantation for those
patients who become dialysis-dependent as a result of aHUS.
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Introduction
Thrombotic microangiopathy (TMA) describes a patho-
logical process of microvascular thrombosis, consumptive
thrombocytopenia and microangiopathic haemolytic
anaemia (MAHA), leading to end-organ ischaemia and
infarction affecting particularly the kidney and brain.
Patients may present with acute renal failure and/or cer-
ebral dysfunction, although cardiac, gastrointestinal and
other organ involvement can also occur. TMA is a feature
of a number of clinical disorders including haemolytic
uraemic syndrome (HUS) either due to shiga toxin-
producing bacteria, including Escherichia coli (STEC) and
Shigella dysenteriae Type I, or due to invasive infection with
Streptococcus pneumoniae (pneumococcal- or p-HUS).
Rare but important TMA-related disorders include
non-shiga toxin-mediated, non-pneumococcal, hence
‘atypical’, haemolytic uraemic syndrome (aHUS), and
thrombotic thrombocytopenic purpura (TTP). TMA may
also occur in other conditions including malignant hyper-
tension (HT), pregnancy, and renal transplantation (rejec-
tion or drug toxicity). Several molecular mechanisms
mediating TMA have been elucidated in the past decade
via human gene association studies, and in both in vitro
experiments and animal models. However, challenges
remain in distinguishing speciﬁc causes of TMA in the
presence of overlapping clinical features. We review the
pathophysiology of TMA and provide a guide to diagnosis
and treatment drawing on existing guidelines. These rec-
ommend ‘urgent and empirical’ therapeutic plasma ex-
change (TPE), provided that childhood STEC and
invasive pneumococcal infection have been excluded [1].
Laboratory features of TMA
The term TMA was coined in 1952 to describe post-
mortem ﬁndings of ‘widely disseminated thrombosis of
the smallest calibre blood vessels’ [2]. It was clear that
laboratory features (Table 1) could identify TMA ante-
mortem, though recognition that MAHA indicated ‘direct
contact between red cells and the diseased blood vessels’
came later [3]. Endothelial damage and thrombosis within
the microvasculature create abnormally high shear stress,
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leading to platelet aggregation and red cell destruction. As
the haemolysis is not immune-mediated, the Coombs test
(or ‘direct antiglobulin test’) should be negative. However,
a positive Coombs test may be seen in associated auto-
immune conditions such as systemic lupus erythematosus
(SLE), or alloimmunity (e.g. following blood product
transfusion). The Coombs test may also be positive in
neuraminidase-mediated p-HUS. Elevated serum lactate
dehydrogenase (LDH) reﬂects haemolysis and/or tissue
ischaemia and is useful both diagnostically and in moni-
toring disease activity. Disseminated intravascular coagu-
lation is usually distinguishable from TMA on the basis of
abnormal clotting parameters and typically less marked
thrombocytopenia [4].
Renal biopsy features of TMA
Renal histological features of TMA on light microscopy
include arteriolar and/or glomerular intracapillary throm-
bosis, often with accumulation of fragmented erythrocytes
within capillary lumens, and focally ischaemic or con-
gested glomerular tufts. Severe arterial and arteriolar
injury may be seen with or without widespread thrombo-
sis, usually in the setting of malignant HT. However, renal
biopsy is rarely performed in patients with renal manifes-
tations of TMA as little aetiological or prognostic infor-
mation is added to that obtained from basic laboratory
tests. One exception is post-renal transplantation, where a
biopsy may be required to distinguish antibody-mediated
rejection from other potential causes of TMA. Native
renal biopsy may also be of value where an alternative (or
coexistent) lesion is suspected (e.g. glomerulopathy). In
chronic TMA, a membranoproliferative pattern with
‘double contours’ of the glomerular basement membrane
may develop, usually lacking the immune deposits charac-
teristic of glomerulonephritis.
Clinical disorders associated with TMA
TTP [5] and HUS [6] were initially described as distinct
clinical entities, both manifesting TMA. A paradigm arose
whereby TMA with signiﬁcant dysfunction of the central
nervous system (CNS), severe thrombocytopenia, fever and
relative renal sparing was designated as TTP, while the
term HUS was applied to cases with predominant renal in-
volvement without neurological features. One autopsy
series appeared to support this distinction, suggesting that
HUS-associated renal lesions were more severe and
contained ﬁbrin-rich thrombi, as opposed to the platelet-
rich thrombi seen in TTP [7]. However, it has become ap-
parent that considerable clinical overlap exists, prompting
the use in some publications of the composite term ‘HUS/
TTP’. Advances in the biological understanding of TMA
suggest that an aetiological classiﬁcation (rather than one
based on clinical features) should provide a better guide to
prognosis and therapy. The system proposed by the Euro-
pean Paediatric Research Group for HUS [8] incorporates
both deﬁned aetiologies and disease ‘associations’ where
causality is not yet ﬁrmly established (Table 2).
This review addresses the major aetiologies of TMA,
and the inherent difﬁculties in linking disease mechan-
isms to clinical phenotypes. Although a predominant
renal picture is characteristic of STEC-HUS, CNS compli-
cations can occur [9], with the same being true of aHUS
related to complement dysregulation [10]. Conversely, TTP
associated with severe deﬁciency of ADAMTS13 may
sometimes present with renal failure and/or without neuro-
logical features [11, 12]. Disease ‘associations’ of TMA are
also discussed, although in some cases it is unclear
whether these are causative of TMA or precipitants in a ge-
netically or immunologically susceptible individual. The
importance of triggering factors is exempliﬁed by the fre-
quent occurrence of preceding illnesses including gastroen-
teritis and upper respiratory tract infections in large cohorts
of patients presenting with aHUS [13–15]. Malignant HT
may be either a cause of TMA or a manifestation of renal
involvement from an underlying disorder such as aHUS
[15]. The interplay of constitutional defects and
Table 1. Laboratory features of TMA
Full blood count: severe thrombocytopenia and anaemia
Blood ﬁlm: red cell fragmentation (‘schistocytosis’ >1%), also
polychromasia (reticulocytosis), absent or giant platelets
Coombs test: negative
Haemolysis screen: hyperbilirubinaemia (unconjugated), elevated LDH
and reticulocyte count, low serum haptoglobins, free haemoglobin in
serum and urine
Liver enzymes and coagulation screen: normal
Serum creatinine: elevated in renal involvement
Table 2. Classiﬁcation of HUS, TTP and other TMA-associated
disorders
Established aetiologies
Infection-induced
Shiga toxin-associated: E. coli (STEC), Shigella dysenteriae Type 1
and other bacteria
Invasive infection with Streptococcus pneumoniae (p-HUS)
Complement dysregulation
Genetic
Acquired
ADAMTS13 protease deﬁciency
Genetic
Acquired (including ticlopidine)
Defective cobalamin (B12) metabolism
Quinine
Disease associations
HIV and other viral infections
Malignancy, cancer chemotherapy, ionizing radiation
Transplantation
Allogeneic HSCT
Solid-organ transplantation
Calcineurin inhibitors
Pregnancy
HELLP syndrome
Oral contraceptive pill
Connective tissue disorders
SLE
Antiphospholipid syndrome
Glomerulopathy
Pancreatitis
Malignant hypertension
VEGF-inhibitors
Other familial
Adapted from Besbas et al. [8].
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environmental triggers necessitates broad aetiological con-
sideration in patients presenting with features of TMA, and
testing for defects in complement regulation and von Will-
ebrand factor (vWF) processing.
Shiga toxin-associated HUS
Clinical features
HUS complicating enteric infection with shiga toxin-pro-
ducing bacteria was identiﬁed in 1983 [16] and is an
important cause globally of acute renal failure in child-
hood. STEC is the main pathogen in developed countries,
accounting for over 90% of HUS cases [17]. STEC-HUS
(also called diarrhoea-positive, D+HUS) typically presents
as renal failure following a bloody diarrhoeal prodrome.
The prognosis in children is generally favourable with
supportive measures (including dialysis) [18], in contrast
to p-HUS where mortality among infants is around 25%
despite treatment [19]. The largest recorded outbreak of
STEC-HUS was centred in Germany in May 2011. The
epidemic was notable for adult predominance (especially
females) and high mortality during the acute phase of
illness, with 36 deaths among the 845 cases (4.3%) [20].
In addition to renal failure, a signiﬁcant proportion of
patients developed neurological sequelae late in the
disease [21]. Available information suggests that children
(representing around 12% of cases) were less severely af-
fected, with one death among over 90 cases [22].
Pathophysiology
The natural reservoirs of STEC are sheep and cattle intes-
tines, with bacterial transmission to humans occurring pre-
dominantly through consumption of raw or undercooked
food products, or contaminated water. STEC O157:H7 is
the serotype most commonly identiﬁed in HUS cases,
easily distinguished after the culture of stool or rectal swab
owing to its inability to ferment sorbitol when plated on
MacConkey agar. Non-O157 serotypes behave less charac-
teristically on culture media, and hence, the identiﬁcation
of shiga toxin using molecular techniques is often required
for diagnosis [23]. During the German outbreak, toxico-
logical assays for shiga toxin and/or polymerase chain reac-
tion (PCR) of the shiga toxin gene preceded serotyping of
the unexpected causative strain, STEC O104:H4. This sero-
type is non-zoonotic, and the source for human trans-
mission was eventually traced to bean sprouts [24].
Once ingested, STEC adheres to intestinal mucosa, se-
creting shiga toxin which enters the bloodstream and is
transported by leucocytes to target organs [17]. Shiga
toxin exerts its cytotoxic and apoptotic effects after attach-
ing to high-afﬁnity globotriaosylceramide 3 receptors
which are highly expressed on glomerular endothelial
cells (ECs). Injury to the endothelium produces a pro-
thrombotic EC phenotype, leading to the activation of
platelets, leucocytes, and the coagulation cascade. Shiga
toxin-mediated activation of the alternative pathway (AP)
of complement may be an additional factor in the patho-
genesis of STEC-HUS [17]. As HUS occurs in a minority
of STEC-infected individuals, its development could be
inﬂuenced by constitutive abnormalities in complement
regulation. This has been reported in a patient with HUS
following infection with STEC, in whom an aHUS-
associated mutation was detected [25]. However,
mutations were not identiﬁed in three children treated suc-
cessfully for STEC-HUS with the anti-C5 complement
agent eculizumab [26]. No systematic evaluation of comp-
lement genetics in patients with STEC-HUS has yet been
published.
Atypical haemolytic uraemic syndrome
Clinical phenotype
aHUS is a rare disease associated which genetic or acquired
factors that cause defective regulation of the alternative
complement pathway [27]. Clinical features of aHUS are in-
distinguishable from other causes of TMA, renal involve-
ment being predominant but extrarenal (including severe
neurological [10] or cardiac [28]) manifestations also promi-
nent in some patients. Although aHUS often presents in
childhood, at least one series found that the initial presen-
tation in 36% of genetically predisposed individuals was in
adulthood (including an 86 year old) [14]. While a diar-
rhoeal prodrome is less common than in STEC-HUS, a pre-
ceding episode of gastroenteritis is reported in one-quarter
of childhood aHUS episodes [13, 15], with similar ﬁndings
in adult aHUS [29]. Individuals sometimes present with re-
lapsing disease and/or a family history of aHUS. The prog-
nosis of aHUS is poor compared with STEC-HUS, with a
3-year composite endpoint of death and end-stage kidney
disease (ESKD) occurring in 53% (signiﬁcantly worse in
adults than in children) [14].
Pathophysiology: complement dysregulation
The complement system comprises over 30 proteins
pivotal to innate immunity and inﬂammation. Comp-
lement activation occurs by proteolysis in three pathways:
the classical pathway, lectin pathway and AP (Figure 1).
The AP is unique in that continuous, low-level activation
occurs in the circulation due to spontaneous hydrolysis of
C3 (so-called ‘C3 tickover’). C3 activation produces the
anaphylatoxin C3a and an opsonic fragment, C3b, which
tags microbial or altered host cell surfaces for phagocyto-
sis. C3b is also able to bind complement factor B,
forming the catalytic C3 convertase of the AP (C3bBb).
The AP C3 convertase ampliﬁes C3 activation via a posi-
tive feedback mechanism both in the circulation (‘ﬂuid-
phase’) and, following deposition of C3b, on cell sur-
faces. Binding of additional C3b fragments to the AP C3
convertase generates a C5 convertase, responsible for the
activation of C5. C5 activation yields the anaphylatoxin
and chemoattractant C5a together with C5b, which
initiates assembly of the terminal complement pathway
C5b-9 (or membrane attack complex, MAC). MAC forms
lytic pores on cell surfaces, while on ECs, sublytic levels
of MAC can impair cellular function, culminating in a
prothrombotic phenotype [30].
Several regulatory proteins inhibit ampliﬁcation of the
AP (Figure 2). Complement factor H blocks the formation
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of the AP C3 convertase and accelerates its breakdown.
Factor H is also a cofactor for complement factor I-
mediated proteolysis of C3b to generate the ‘inactivated’
fragment iC3b, which is unable to bind factor B to form
the AP C3 convertase. In addition to ﬂuid-phase activity,
factor H can attach to negatively charged molecules on cell
membranes to perform its regulatory function on the cell
surface. Membrane cofactor protein (MCP/CD46) is ex-
pressed exclusively on cell surfaces, where it provides
additional cofactor activity for factor I. AP complement
dysregulation involves uncontrolled complement activation
as a result of deﬁcient or functionally impaired regulatory
proteins, or hyperactive AP C3 convertase components.
The fenestrated endothelium of the glomerulus may be par-
ticularly susceptible to AP complement dysregulation [30],
explaining the renal predilection of TMA in aHUS.
However, the precise mechanisms by which microvascular
thrombosis ensues are not yet fully known.
Genetics of aHUS: factor H
The association between aHUS and AP complement dys-
regulation was ﬁrst noted in 1973 when low plasma C3
levels were detected in some affected patients [31]. The
occurrence of aHUS in multiple members of the same
family (ﬁrst noted in concordant monozygous twins [32])
suggested a genetic basis for disease. A linkage study in
three kindreds with the aHUS phenotype localized the
defect to the regulators of complement activation (RCA)
region on chromosome 1q32 [33]. A candidate gene ap-
proach identiﬁed mutations in the CFH gene encoding
factor H (low levels of which had been noted in affected
families [34]). It is now recognized that sporadic aHUS
signiﬁcantly outnumbers familial cases and that heterozy-
gous CFH mutations are the most common cause. The
majority are missense, single-point mutations in exons en-
coding the C-terminus domain responsible for factor H
binding to ECs and to surface-bound complement frag-
ments [35]. Such mutations cause loss of complement
regulation at the glomerular surface, whereas ﬂuid-phase
regulation is maintained by circulating factor H. The
pathogenic role of mutant factor H with impaired surface
binding is supported by a transgenic mouse model in
which expression of only factor H lacking the C-terminal
region led to spontaneous TMA [36]. Less commonly,
aHUS-associated CFH mutations affect the N-terminus
protein domain resulting in defective binding to C3b or
reduced cofactor activity for factor I [37]. Mutations
leading to reduced levels of circulating factor H may also
cause aHUS, typically accompanied by low C3 levels
[34]. However, the complete absence of ﬂuid-phase regu-
lation as a consequence of homozygous factor H
deﬁciency is associated with dense deposit disease [38].
Autoantibodies that bind the C-terminal portion of factor
H have also been identiﬁed as a cause of aHUS [39], pro-
ducing a functional defect mimicking CFH mutations [40].
These autoantibodies may be found in isolation, or accom-
panying homozygous deletion of the genes encoding
complement factor H-related proteins [41, 42] (especially
CFHR1 [43]) or occasionally other mutations [44]. The
ﬁve CFHR genes are positioned adjacent to CFH in the
RCA region, where a high degree of sequence homology
predisposes to genomic rearrangements including deletions
and the formation of rare hybrid CFH-CFHR genes [45,
46] in association with aHUS.
Genetics of aHUS: registry data
The frequency of CFH mutations, factor H autoanti-
bodies, and mutations in other complement-related genes
Fig. 1. Initiation of complement activation, with ampliﬁcation and downstream effects of the AP.
Fig. 2. Regulation of the AP of complement.
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in a number of aHUS cohorts has been published
(Table 3). The Italian-based International Registry of Re-
current and Familial HUS/TTP [14] (comprising 273
adult and paediatric patients) and several paediatric series
[13, 15, 47] also provide detailed clinical outcome data.
CFH mutations, in addition to being the most common,
are associated with the highest rate of adverse outcomes.
Despite signiﬁcant response of CFH-aHUS to plasma
therapy, ESKD and death have been reported in the ﬁrst
year in 50–70% of patients (increasing thereafter). Patients
with MCP mutations [48, 49] typically have no response
to plasma therapy, remit spontaneously and have a better
long-term prognosis, despite multiple relapses. CFI
mutations [50] are associated with a variable prognosis
intermediate between that of CFH and MCP mutations.
This phenomenon may be explained by the high proportion
of patients with CFI mutations having an additional
mutation in another complement-related gene associated
with a more severe phenotype [51]. Recently, factor I auto-
antibodies have been identiﬁed in three patients with
aHUS, although their role in disease is uncertain [52]. A
single patient is reported with aHUS and a familial
mutation in the CLU gene on chromosome 8p21 encoding
clusterin [53]. Mutant clusterin displayed a reduced ability
to inhibit MAC formation in vitro, although aHUS in this
individual may equally have been attributable to a coexist-
ing MCP mutation. In addition to ‘loss-of-function’
mutations in regulatory proteins, ‘gain-of-function’
mutations in the genes encoding C3 [54] and factor B [55]
have been reported in aHUS patients. These produce AP
C3 convertase components that are hyperfunctional or
resistant to inhibition by complement regulatory proteins.
Mutations in the THBD gene encoding thrombomodu-
lin have also been demonstrated in aHUS cohorts, in
association with comparatively poor outcomes [56].
Thrombomodulin is a membrane-bound protein expressed
on all vascular ECs that has anticoagulant and anti-inﬂam-
matory properties [57]. Originally identiﬁed as a cofactor
for thrombin-mediated activation of protein C, it acceler-
ates the degradation of anaphylatoxins C3a and C5a after
binding thrombin to generate the ﬁbrinolysis inhibitor
procarboxypeptidase B (or ‘thrombin activatable ﬁbrino-
lysis inhibitor’). As yet, the functional basis for THBD
mutations as a cause of aHUS has not been demonstrated,
with limited data indicating that loss of thrombomodulin-
mediated complement regulation via factor I cofactor
activity may be important [56]. In any event, thrombomo-
dulin is an example of potentially important interactions
between the complement and coagulation systems in TMA
pathogenesis [58].
Genetics of aHUS: complotype
Genetic variants within the RCA cluster that are common
on a population basis are also important in determining an
individual’s propensity to complement activation [59].
Single-nucleotide polymorphisms (SNPs) have been
identiﬁed predisposing to aHUS in the CFH [60], MCP
[61] and CFHR1 [43] genes as well as the C4BPA gene
[62] encoding C4b-binding protein. The latter displayed
reduced AP regulatory function via factor I cofactor
activity in vitro, although classical pathway regulation (its
main physiological role) was unimpaired. Two comp-
lement haplotypes (or ‘complotypes’) have been de-
scribed comprising multiple SNPs in CFH [36], one
increasing the risk of aHUS and the other being protec-
tive. MCP haplotypes have also been identiﬁed conferring
either increased risk [63] or protection [64].
Complement assessment in aHUS
Low plasma/serum C3 (not usually C4) is consistent with a
diagnosis of aHUS, but not speciﬁc (also found in some
cases of STEC-HUS, dense deposit disease, SLE etc.). It is
also insensitive, given that the most common CFH
mutations are associated with normal circulating C3 and
factor H levels, while MCP mutations also do not affect C3
levels. However, most MCP mutations result in reduced cell
surface expression of MCP, detectable on peripheral blood
mononuclear cells (PBMCs) using ﬂow cytometry (FACS
analysis). In contrast, low C3 levels are invariably seen in
aHUS patients with C3 mutations, most with CFI mutations
and around half with factor H autoantibodies [47].
Due to the insensitivity of complement protein levels,
genetic and autoimmune tests are often required to ident-
ify a complement-related defect in patients with aHUS.
Utilizing the current array of diagnostic assays, up to
three-quarters of the Italian-based cohort had an identiﬁ-
able aetiological factor [14] (considerably greater than in
some other registries). In pregnancy-associated aHUS, the
yield of mutational analysis is especially high (18 of 21
patients in one cohort having a mutation identiﬁed [65]),
with a pathogenic link to AP complement dysregulation
also established for pre-eclampsia [66] and HELLP (Hae-
molysis, Elevated Liver enzymes and Low Platelets) syn-
drome [67]. However, the presence of a mutation in an
individual with aHUS does not prove causation, with
Table 3. Mutations in aHUS registries
Abnormality Gene (locus) Proportion of aHUS cases (%)
Factor H CFH (RCA: 1q32) 11–29 [15, 14, 61, 64, 70, 171–174]
Membrane cofactor protein (MCP/CD46) MCP (RCA) 3–17 [15, 14, 61, 64, 70, 171–174]
Factor I CFI (4q25) 2–17 [13, 15, 14, 51, 61, 64, 70, 171–174]
C3 C3 (19p13) 2–17 [15, 14, 64, 172, 174]
Factor B CFB (6p21) 0–5 [15, 14, 64, 171–174]
Thrombomodulin THBD (20p11) 0–5 [15, 14, 174]
Hybrid gene CFH-CFHR (RCA) 0–2 [14, 41, 70, 171, 172]
Combined mutations 3–17 [15, 14, 51, 64, 171–174]
Factor H autoantibodies 4–13 [15, 14, 41, 43, 44, 171–173]
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several mutations described that lack functional signiﬁ-
cance [68]. This includes an important analysis of two
CFH mutations widely cited in the aHUS literature, but
more likely to represent rare, non-pathogenic polymorph-
isms [69].
Another complicating factor in genetic assessment is
the incomplete penetrance of aHUS-associated mutations,
exempliﬁed by family studies in which only half those
carrying the identical mutation to the proband manifested
disease [14, 70]. This suggests that several genetic risk
factors may be required for phenotypic expression (the
‘multiple hit’ hypothesis). One pedigree is described in
which only those family members possessing all three in-
herited abnormalities in complement-related genes had
aHUS [71]. The cumulative impact of combined
mutations, compound heterozygosity [72], at-risk SNPs/
haplotypes, and autoantibodies on disease expression is
increasingly recognized. Yet, a majority of aHUS patients
have an additional, environmental trigger such as infec-
tion, pregnancy or drug exposure that precipitates the
onset of aHUS. In some cases, this involves direct endo-
thelial toxicity or an immune process promoting comp-
lement activation. An additional mechanism is suggested
by the development of TMA after therapeutic blockade of
vascular endothelial growth factor (VEGF) [73], involving
loss of the endothelial protection normally provided by
podocyte expression of VEGF [74].
Thrombotic thrombocytopenic purpura
Pathophysiology and clinical features
TTP is an uncommon TMA-related disorder occurring pre-
dominantly in adults [75], in which relapses are common
and mortality remains 15–20% despite TPE [76]. It has
been most closely associated with acquired (or rarely
genetic) severe deﬁciency of the cleaving protease for
vWF, ADAMTS13 (a disintegrin and metalloprotease with
thrombospondin type 1 domains, member 13 of the
family). vWF is important for primary haemostasis, indu-
cing platelet aggregation and thrombus formation at sites
of endothelial injury. Initially secreted by ECs as large
multimers, vWF is degraded into progressively smaller cir-
culating forms by ADAMTS13 under the inﬂuence of
shear stress. An association between TTP and the accumu-
lation of highly thrombogenic ‘ultra large’ (ULvWF) mul-
timers was ﬁrst noted in 1982 [77]. ADAMTS13 was
identiﬁed as the vWF-cleaving protease in 1996 [78, 79],
and its deﬁciency subsequently noted in patients with TTP
[80]. ‘Congenital’ TTP (or Upshaw–Schulman syndrome)
is due to compound heterozygous or homozygous
mutations in the ADAMTS13 gene on chromosome 9q34,
ﬁrst identiﬁed using linkage analysis in four kindreds in
2001 [81]. More than 90 mutations have been described,
most causing impaired protease secretion from ECs, or im-
paired catalytic activity (hence ‘functional’ deﬁciency)
[82]. Penetrance is over 90%; however, congenital TTP ac-
counts for a mere 5% of TTP cases. More commonly,
ADAMTS13 deﬁciency due to an inhibitory autoantibody
(usually IgG [83]) mediates ‘acquired’ TTP. With the
exception of exposure to the antiplatelet agent ticlopidine
[84], factors leading to autoantibodies in acquired TTP are
unknown.
Clinical diagnosis of TTP is based on thrombocytope-
nia (often profound) and MAHAwhere no other cause of
TMA is identiﬁed. The classic diagnostic ‘pentad’ [85]
including also fever, neurological and renal involvement
identiﬁed more advanced TMA (not speciﬁcally TTP)
and is no longer relevant. Neurological features at presen-
tation are common in patients later shown to have severe
ADAMTS13 deﬁciency and were reported as being
severe in 66 and 48% of the patients in the Oklahoma
TTP registry [11] and French TMA Reference Centre
cohort [12], respectively. Progression to ESKD is unusual
with severe ADAMTS13 deﬁciency [86], although renal
abnormalities including proteinuria, haematuria and mild
or transient renal failure occur frequently [11, 12]. Some
overlap between TTP and HUS may be attributable to in-
tersecting pathogenic pathways, with both complement
activation [87] and shiga toxin [88] able to stimulate
vWF secretion from glomerular ECs and/or impair
ADAMTS13 activity in vitro. Administration of shiga
toxin was also required to trigger TMA in a genetically
susceptible mouse strain with homozygous ADAMTS13
deﬁciency [89]. However, the relevance of the murine
model to human TTP is uncertain, given that unprovoked
TMA has not been observed in ADAMTS13 knockout
mice [89, 90]. Injection of baboons with anti-ADAMTS13
antibodies was associated with immediate TTP [91].
ADAMTS13 assessment in TTP
Severe deﬁciency of ADAMTS13 appears to be required to
cause TTP and is variably deﬁned as <5 or <10% of normal
protease activity (with a broad reference range of 40–140%)
[92]. The sensitivity of severe ADAMTS13 deﬁciency for
TTP ranged between 18 and 72% in one meta-analysis [92],
attributable to differences in the proportion of patients en-
rolled with coexisting TMA-associated conditions. TMA in
the setting of severe sepsis, malignancy, solid-organ trans-
plantation, allogeneic haematopoietic stem cell transplan-
tation (HSCT) and some drug exposures is less likely to
involve severe protease deﬁciency. However, in TMA
associated with autoimmune diseases, pregnancy or prior
use of ticlopidine (possibly also clopidogrel), severe
ADAMTS13 deﬁciency is commonly found. The speci-
ﬁcity of severe ADAMTS13 deﬁciency for TTP is contro-
versial, with reports of TTP being diagnosed in patients
with severe protease deﬁciency who are subsequently
found to have systemic infection [93] or malignancy [11].
ADAMTS13 assays provide prognostic information,
with prospective studies suggesting that patients present-
ing with severe ADAMTS13 deﬁciency are more likely to
remit with TPE and have lower mortality [94, 95].
However, this could be due to fewer life-threatening
comorbidities (e.g. metastatic malignancy) in these
patients. Inhibitory autoantibodies identiﬁed during the
acute episode may confer a worse prognosis [96]. Once
patients are in remission, a ﬁnding of severe protease
deﬁciency or inhibitors is associated with increased risk
of relapse, based on retrospective series [97, 98].
2678 T. Barbour et al.
Empirical treatment approach
Diagnostic evaluation (Table 4) and treatment (Table 5) of
TMA-related disorders are initiated concurrently. As clini-
cal features are often unreliable in determining the cause
of TMA, and comprehensive testing takes some time, an
empirical treatment strategy is required in most patients
presenting with MAHA, thrombocytopenia and renal and/
or neurological dysfunction. Guidelines produced in 2009
by the European Paediatric Study Group for HUS rec-
ommend ‘urgent and empirical’ TPE with fresh frozen
plasma (FFP) or solvent-treated plasma, once STEC (and,
if suspected, invasive pneumococcus) have been excluded
in children [1]. Evidence for plasma therapy in children
with STEC-HUS is lacking, with a 2009 Cochrane sys-
tematic review ﬁnding none of the additional measures
used in children with post-diarrhoeal HUS was superior
to supportive care alone [99]. However, this review has
been criticized for the inclusion of studies in which the
aetiology of TMAwas not established, including both the
randomized controlled trials (RCTs) in which plasma in-
fusion was not beneﬁcial [100]. In children with aHUS,
plasma therapy is recommended [1, 101], based on case
reports and registry data, but not prospective trials. TPE is
preferred to plasma infusion although evidence is limited
to a case report showing differential outcomes in twin 5-
year-old girls with a familial CFH mutation [102]. The
volume requirements for plasma infusion in small chil-
dren with renal impairment may necessitate exchange.
Mortality in adults with a clinical diagnosis of TTP,
prior to the widespread use of plasma therapy, was as
high as 90% [85]. In contrast, a 1991 RCT [103] demon-
strated mortality of 22% in adults receiving TPE and 37%
in those receiving plasma infusion (notwithstanding that
the trial population may have had less severe disease at
diagnosis). The 2009 Cochrane review concluded that
TPE is superior to plasma infusion in the treatment of
TTP, with no additional beneﬁt from antiplatelet therapy
or the substitution of cryosupernatant for FFP during ex-
change [99]. As TPE appears to be beneﬁcial irrespective
of severe protease deﬁciency [11], treatment should not
be delayed while awaiting results of ADAMTS 13 testing.
In patients known to have the congenital form of TTP,
isolated infusion of plasma (ﬁrst described with success
over 50 years ago [104]), cryoprecipitate or plasma-
derived vWF concentrates is the current recommendation
[105].
Owing to the greater likelihood of TTP in adults, and its
potentially fulminant course [106], many centres perform
TPE empirically in adults even prior to the exclusion of
STEC-HUS [107]. If plasma therapy is commenced empiri-
cally, the results of STEC and ADAMTS13 assays guide
further management. In those with severe ADAMTS13
deﬁciency and no evidence of STEC infection, consider-
ation may be given to adjunctive immunosuppressive treat-
ment for TTP (discussed below). The diagnosis remains
uncertain if neither STEC infection nor severe protease
deﬁciency is found, although many such patients (especially
those with signiﬁcant renal failure) will have aHUS. This
patient group matches the inclusion criteria for aHUS in
Phase II trials reporting beneﬁt with eculizumab (discussed
below). In adult cases where STEC infection is diagnosed
after TPE has been started, consideration may be given to
stopping TPE. However, some groups advocate TPE in
adults with STEC-HUS, particularly in the presence of
severe renal or neurological involvement [108]. This is
despite the absence of data from appropriately controlled
trials, with published evidence consisting until recently of a
single retrospective cohort analysis in elderly patients [109].
TPE was frequently used during the recent German STEC-
Table 4. Diagnostic tests
Shiga toxin
Stool culture for E. coli plus either toxicology for shiga toxin or PCR
for shiga toxin gene
Urine culture for E. coli
Other bacterial testing as indicated
S. pneumoniae
T antigen expression on red cells
PCR of blood and/or secretions
Blood culture
Complement dysregulation
Plasma/serum protein levels
C3
Factor H, factor I, factor B
MCP (CD46) expression on PBMCs
Factor H autoantibodies
Mutations
Direct exon sequencing of CFH, MCP, CFI, CFB, C3
Copy number variation across CFH-CFHR locus
ADAMTS13 deﬁciency
ADAMTS13 activity
ADAMTS13 autoantibodies
ADAMTS13 mutations
Other associations
Pregnancy test
Liver and pancreas enzymes
Cobalamin (B12), homocysteine assay, methylmalonic acid (plasma
and urine) ± mutation analysis of MMACHC gene
HIV and other viral serology as indicated
ANA, lupus anticoagulant, antiphospholipid antibodies
Pharyngeal swab and viral PCR for inﬂuenza A (H1N1)
Table 5. Treatment
(i) Supportive measures only
Paediatric STEC-HUS and invasive pneumococcal infection (p-HUS)
Cobalamin deﬁciency (children), HSCT- or malignancy-associated
TMA, malignant HT
(ii) Therapeutic plasma exchange (TPE)
First exclude paediatric STEC-HUS and p-HUS
Recommended in all other settings
Including TTP and aHUS (probably of no beneﬁt in MCP-aHUS)
Controversial in adult STEC-HUS
Plasma infusion recommended in known congenital TTP
(iii) Eculizumab
aHUS
(iv) Steroids and/or rituximab
Possibly in acquired TTP and aHUS with factor H autoantibodies
(v) Renal transplantation for ESKD
STEC-HUS
MCP-aHUS
Living-related donation contraindicated
(vi) Prophylactic strategies in high-risk transplantation (i.e. non-MCP
aHUS)
Intensive perioperative TPE
Eculizumab
Rituximab (for factor H autoantibodies)
Combined kidney–liver transplantation
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HUS outbreak [21], mostly in adults with severe disease but
also in some children [22]. A Danish subset of ﬁve adult
patients has been reported with apparent beneﬁt [110],
while other outcome data are awaited. Uncontrolled reports
of the efﬁcacy of immunoadsorption in patients with severe
neurological complications of STEC-HUS during this epi-
demic [111] and one other [112] have also been published.
In a restricted number of settings, TPE is deferred or
ceased. This includes cobalamin (vitamin B12) deﬁciency
in children, for which screening is recommended and
treatment with parenteral hydroxycobalamin is effective.
In adults with HSCT- or malignancy-associated TMA,
plasma therapy is not generally thought beneﬁcial. Blood
pressure control is essential for patients with malignant
HT as a cause of TMA, although the possibility of under-
lying aHUS or TTP should be recognized, and consider-
ation also given to starting TPE. Where TPE is indicated
but not immediately available, plasma infusion should be
commenced pending urgent transfer to a centre offering
TPE. If clinical or biochemical response is not attained,
or relapse recurs, TPE may be intensiﬁed either by in-
creasing the volume of exchange or performing twice-
daily TPE. Additional strategies for refractory or relapsing
disease are discussed below. In both TTP [113] and aHUS
[114], opinion is divided as regards weaning or prompt
cessation of TPE following a response to treatment.
Eculizumab in aHUS
Eculizumab is a humanized monoclonal antibody inhibit-
ing C5 activation, a critical effector mechanism in the
murine model of aHUS [115]. Recently approved in the
USA and Europe as ﬁrst-line treatment for aHUS, eculizu-
mab was initially reported with efﬁcacy in cases that were
refractory to plasma therapy and/or relapsing [116–121],
including after renal transplantation (discussed below).
Interim data (published in abstract form only) from pro-
spective, uncontrolled Phase II trials show a favourable
response in patients with plasma-resistant [122] and
plasma-dependent [123] aHUS. Whereas maintenance
therapy appears to be effective [124] and was used in
the clinical trials, discontinuation has been reported anec-
dotally with severe relapse [125, 126]. The question of
long-term use of eculizumab in aHUS requires further
evaluation in clinical trials, especially in view of the very
high cost of treatment. Based on reports in pregnant
women with paroxysmal nocturnal haemoglobinuria, use
of eculizumab in pregnancy may be safe [127]. Inhibition
of C5 activation creates vulnerability to meningococcal in-
fections, and immunization with a polyvalent meningococ-
cal vaccine is mandatory prior to initiation of eculizumab.
Patients remain susceptible to serotypes not covered by the
vaccine. Prompted by a report of its successful use in three
children with STEC-HUS [26], eculizumab was exten-
sively used in adults during the STEC-HUS epidemic in
Germany, forming the basis for Phase II and III clinical
trials (ClinicalTrials.gov NCT01410916). However, eculi-
zumab is not currently approved for this indication.
While many patients with aHUS respond initially to
plasma therapy (over two-thirds of those treated in the
Italian-based cohort achieving at least a partial response
[14]), overall outcomes are poor. Together with the approval
of eculizumab, this has prompted a reappraisal of the
reliance of empiric treatment protocols on TPE alone. For
example in a child in whom STEC-HUS and pneumococcal
sepsis have been excluded, a provisional diagnosis of
aHUS is arguably sufﬁcient for the commencement of ecu-
lizumab. Similar considerations regarding the empirical use
of eculizumab may arise in adults with predominant renal
manifestations of TMA in whom STEC and ADAMTS13
testing is negative. One suggested strategy in this category
of adult patients involves switching to eculizumab if
initial response to TPE is poor [128]. Regardless of the
initial treatment approach, a provisional diagnosis of aHUS
should prompt investigations for complement dysregulation
including protein levels, gene sequencing and structural
analysis and autoantibody testing (cognisant that comp-
lement protein concentrations are altered if TPE is begun).
Immunosuppression
In TTP, the overall response to plasma therapy is ∼80%
[129], although one-third of patients entering remission
will subsequently relapse [11]. As most TTP is auto-
immune, patients who respond poorly or relapse often
receive adjunctive immunosuppressive therapy with TPE.
Some groups recommend steroids in all patients suspected
of having acquired TTP [113], although this has not been
assessed in a placebo-controlled trial. One RCT compared
intravenous methylprednisolone in a high-dose (10 mg/kg/
day for 3 days, then 2.5 mg/kg/day) versus low-dose (1
mg/kg/day) regimen in 60 patients receiving TPE for acute
new-onset or relapsing TTP [130]. A signiﬁcant increase in
complete remission rate at 23 days was observed in the
group receiving high-dose steroids; however, this group
had also received more TPE following a statistically non-
signiﬁcant beneﬁt at 9 days (the primary study outcome). A
correlation between steroid responsiveness and the severity
of ADAMTS13 deﬁciency or presence of inhibitors has
not been shown although in some studies, immunosuppres-
sive use was restricted to cases of severe protease
deﬁciency [131]. Evidence for steroids in aHUS is lacking
(notwithstanding a theoretical beneﬁt in those with factor
H autoantibodies).
The anti-CD 20 monoclonal antibody rituximab has
been assessed prospectively in small series of adult TTP
either refractory to TPE [131–133] or relapsing [131, 133,
134]. While rituximab was safe and appeared to be ben-
eﬁcial in inducing remission (usually in conjunction with
TPE and steroids), median follow-up periods were less
than 1 year. A recent prospective, non-randomized Phase
II trial of adjunctive rituximab involving 34 adults with
new-onset TTP, and an additional 6 patients with an acute
relapse of TTP, showed a lower relapse rate at a median
follow-up of 27 months compared with historical controls
[134]. Alternative immunosuppressive therapies for TTP,
including vincristine, cyclophosphamide, cyclosporine as
well as splenectomy, lack prospective data and are now
used infrequently. A number of novel agents designed to
block vWF interaction with its platelet receptor are
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undergoing clinical evaluation [135]. Isolated reports in
patients with factor H autoantibody-associated aHUS
suggest beneﬁt with immunosuppressive medications [47,
135] and rituximab [47, 136].
Transplantation
In the rare setting of ESKD due to STEC-HUS, transplan-
tation is generally recurrence-free. In contrast, recurrence
of aHUS was reported in 60% of transplant recipients in
one meta-analysis, with over 90% subsequent graft loss
despite plasma therapy [137]. Genetic analysis enables a
more reﬁned prediction of recurrence [138] and is an es-
sential component of pre-transplant assessment for
patients with aHUS. In those with CFH mutations (the
most commonly recognized genetic abnormality), the risk
of recurrent disease is in the order of 80% [137], whereas
for MCP-aHUS, the recurrence rate is low. This is pre-
sumably because wild-type MCP expressed in the vascu-
lar endothelium of the donor kidney restores local
complement regulation. Recurrent MCP-aHUS has been
reported where microchimaerism was observed within
graft endothelium [139] and in patients with additional
CFH or CFI mutations [140] (despite the earlier sugges-
tion that allograft expression of MCP might be protective
[141]). Overall, poor outcomes are reported for all non-
MCP mutations [13, 14, 55, 137], factor H autoantibodies
[47] and cases where no underlying defect has been de-
monstrated. Living-related renal transplantation is contra-
indicated, regardless of the results of genetic screening,
because of the risk of familial disease due to unrecog-
nized genetic susceptibility factors. In addition to the risk
of recurrence in recipients, there have been reports of
aHUS in the previously asymptomatic related kidney
donors [142], seemingly triggered by donor nephrectomy.
Treatment of recurrent or de novo aHUS post-transplan-
tation, consisting of TPE (with or without reduction in cal-
cineurin inhibitors), has often been unsuccessful [143].
Response to eculizumab has been reported in plasma-re-
fractory cases [144–149] and in the Phase II trials [122,
123] (notwithstanding additional reports of graft loss in
patients who had received a single dose of eculizumab
[114, 138]). In recipients at high risk of recurrence due to
non-MCP mutations, a perioperative strategy involving in-
tensive TPE has been reported with good long-term results
[150–153] (but also with one graft failure following a
reduction in frequency of exchanges [150]). Prophylactic
administration of eculizumab is reported as effective either
alone or in combination with TPE [154–157]. In patients
with factor H autoantibodies, successful transplantation has
been reported with intensive perioperative TPE [158],
coadministration of rituximab [47, 136] or neither [159].
An alternative strategy in ‘high-risk’ patients with non-
MCP-aHUS is combined kidney–liver transplantation, with
the transplanted liver correcting complement dysregulation
through production of wild-type complement proteins
[160]. However, this procedure is associated with signiﬁ-
cant morbidity and mortality, with poor outcomes initially
reported in children with CFH mutations and life-threaten-
ing disease [161–163]. These have been followed by
several successful reports in CFH-aHUS [164–166], and
one each in CFB-aHUS [167] and combined CFH/CFI-
aHUS [168], using pre- and post-operative TPE, heparin
and low-dose aspirin. Guidelines to patient selection for
combined liver–kidney transplantation have been published
[169]. A single case is reported also of pre-emptive isolated
split liver transplant with good graft and native renal func-
tion at 2 years [170].
Conclusions
The past decade has seen an extraordinary increase in the
understanding of molecular mechanisms mediating TMA,
signiﬁcantly changing approaches to diagnosis and treat-
ment. In accordance with international guidelines, the
current mainstay of treatment is the ‘urgent and empirical’
institution of plasma therapy, once paediatric STEC and in-
vasive pneumococcal infection are excluded. Molecular di-
agnostic techniques are becoming more widely available and
are critical to risk stratiﬁcation for transplantation. Emerging
evidence suggests that anti-complement C5 therapy with
eculizumab is effective in aHUS. The enrolment of patients
with STEC-HUS, aHUS and TTP into registries and clinical
trials should further reﬁne empiric treatment and facilitate an
evidence-based shift towards more speciﬁc and effective
therapies. An exciting era beckons where the inexorable pro-
gression to ESKD, systemic complications and premature
death may be interrupted, with the prospect of renal recovery
and long-term avoidance of recurrent disease.
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